IDEXX Laboratories (IDXX) is a publicly traded Healthcare sector company. As of May 20, 2026, IDXX trades at $551.48 with a market cap of $43.05B and a P/E ratio of 40.37. IDXX moved +1.27% today. Year to date, IDXX is -18.86%; over the trailing twelve months it is +7.04%. Its 52-week range spans $356.14 to $769.98. Analyst consensus is buy with an average price target of $693.17. Rallies surfaces IDXX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
IDEXX jumps after Q1 beat and higher 2026 EPS outlook to $14.45–$14.90: IDEXX Laboratories shares are higher after the company reported first-quarter 2026 results and raised its full-year 2026 EPS outlook to $14.45–$14.90. The updated forecast reflects expectations for higher revenue, comparable operating-margin expansion, and updated foreign-exchange assumptions.
| Metric | Value |
|---|---|
| Price | $551.48 |
| Market Cap | $43.05B |
| P/E Ratio | 40.37 |
| EPS | $13.69 |
| Dividend Yield | 0.00% |
| 52-Week High | $769.98 |
| 52-Week Low | $356.14 |
| Volume | 435.42K |
| Avg Volume | 0 |
| Revenue (TTM) | $4.45B |
| Net Income | $1.10B |
| Gross Margin | 62.05% |
7 analysts cover IDXX: 0 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $693.17.